| Literature DB >> 36010116 |
Keshani Weragama1, Poonam Mudgil1, John Whitehall1.
Abstract
Antimicrobial resistance is a growing public health crisis, propelled by inappropriate antibiotic prescription, in particular the over-prescription of antibiotics, prolonged duration of antibiotic therapy and the overuse of broad-spectrum antibiotics. The paediatric population, in particular, those presenting to emergency settings with respiratory symptoms, have been associated with a high rate of antibiotic prescription rates. Further research has now shown that many of these antibiotic prescriptions may have been avoided, with more targeted diagnostic methods to identify underlying aetiologies. The purpose of this systematic review was to assess the impact of rapid diagnostic testing, for paediatric respiratory presentations in the emergency setting, on antibiotic prescription rates. To review the relevant history, a comprehensive search of Medline, EMBASE and Cochrane Database of Systematic Reviews was performed. Eighteen studies were included in the review, and these studies assessed a variety of rapid diagnostic testing tools and outcome measures. Overall, rapid diagnostic testing was found to be an effective method of diagnostic antibiotic stewardship with great promise in improving antibiotic prescribing behaviours. Further studies are required to evaluate the use of rapid diagnostic testing with other methods of antibiotics stewardship, including clinical decisions aids and to increase the specificity of interventions following diagnosis to further reduce rates of antibiotic prescription.Entities:
Keywords: antibiotics; antimicrobial resistance; diagnostic antibiotic stewardship; paediatric emergency department; paediatrics; rapid diagnostic testing; respiratory tract infections
Year: 2022 PMID: 36010116 PMCID: PMC9406643 DOI: 10.3390/children9081226
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Search Strategy.
| Population/Phenomena | Concept | Context | Context | |
|---|---|---|---|---|
| Free Text (title and abstract) | (child * or P#ediatric * or Toddler* or Babies or baby or Teen* or Adolescen* or Youth* or Pre-schooler* or preschooler*).ti,ab. | ((Rapid OR molecular OR admission) adj2 (diagnostic OR respiratory OR antigen)).ti,ab. | ((Emergency OR acute OR critical OR urgent OR crisis OR admitting) adj2 (care OR unit OR ward OR service OR room OR department OR setting)).ti,ab. | (antibiotic OR antimicrobial).ti,ab.data |
| Index Terms | adolescent/or child/or child, preschool/or infant/ | diagnostic techniques, respiratory system/or diagnostic tests, routine/Molecular Diagnostic Techniques/ | Critical Care/admitting department, hospital/or emergency service, hospital/ | Antibacterial agents/ |
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Flow Diagram of Study Selection Process.
Diagnostic Stewardship–The Impact of Rapid Diagnostic Testing for Paediatric Respiratory Presentations in the Emergency Setting: A Systematic Review.
| Author; Year, Country; Study Period; Setting | Study Design; Population and Sample Size | Objective | Intervention | Key Findings |
|---|---|---|---|---|
| Ayanruoh et al., 2009 [ | Retrospective Cohort; patients aged 3–18 years old, n = 8280 | Assess the impact of RDTs on antibiotic prescriptions in children with pharyngitis in the ED | Rapid Streptococcal Test for GAS | Introduction of RDTs was associated with a lower antibiotic prescription rate from 41.38% pre-RDT and 22.45% post-RDT, |
| Bird et al., 2021 [ | Pragmatic AB single-subject study; children aged 6 months to 16 years presenting to ED with a sore throat, n = 605 | Assess efficacy of RDT for GAS combined with established clinical scoring system (McIsaacs Score) in reducing antibiotic prescribing for sore throat | McIsaac clinical score combined with GAS RDT to screen for and treat GAS pharyngitis | Baseline rates of antibiotic prescription rate 79% was reduced to 24% following the implementation of intervention. |
| Busson et al., 2017 [ | Cohort study; paediatric patients (<15 years old) presenting to ED with fever of unknown source, suspected influenza, or complicated illness | Evaluate the contribution of the Alere i Influenza A&B test to patient management | Alere i Influenza A&B test | Antibiotics were avoided in 36.2% of patients (20 paediatric patients, 5 adult patients). |
| Cardoso et al., 2013 [ | Cohort study; patients aged between 2 and 15 years with history of sore throat and fever, no signs of viral infection, n = 650 | Evaluate the impact of RDTs on the diagnosis and treatment of children with acute pharyngotonsillitis | Clearview Strep A Test (Oxoid), which consists of a rapid immunoassay for the qualitative detection of group A streptococcal antigens (RADT) | Implementation of RDT prevented unnecessary antibiotic prescription in 32.9% of cases. |
| Crook et al., 2020 [ | Before-and-after intervention study; children aged < 90 days presenting to ED with fever or hypothermia, n = 5317 | Assess the impact of clinical guidelines and RDTs on paediatric patient management | BioFire FilmArray Respiratory Panel 2 & mPCR testing with clinical guidelines | Introduction of RDT was associated with a significant reduction in antibiotic prescription in children aged 29–60 days old. |
| Doan et al., 2009 [ | RCT; children 3 to 36 months of age with febrile acute respiratory tract infections at a paediatric ED, n = 204 | Assess whether early and rapid diagnosis of a viral infection alleviates the need for ancillary testing and antibiotic treatment | Rapid respiratory viral testing program, named VIRAP (for Viral Rapid Program) | No statistically significant difference in ED length of visits, rate of ancillary testing, or antibiotic prescription rate in the ED between the study groups. |
| Echavarria et al., 2018 [ | Prospective, randomized, non-blinded study; patients aged 2 months–6 years of age (children) or greater than 18 years (adults), with signs/symptoms of acute lower respiratory infection with onset within the preceding 7 days | Determine if timely etiological diagnosis has an impact on medical management in relation to antibiotic and antiviral prescription, and use of complementary studies | BioFire FilmArray Respiratory Panel 2 or immunofluorescence assay (IFA) | Diagnosis with FilmArray-RP was associated with significant changes in medical management including withholding antibiotic prescriptions in children (OR: 12.23, 95% CI: 1.56–96.09). |
| Esposito et al., 2003 [ | RCT; patients aged 0–15 years attending ED because of influenza-like illness, n = 957 | Assess the effect of a rapid diagnosis of influenza infection on the management of children with influenza-like illness in an ED | Quickvue Influenza Test | Patients with a positive Quickvue test were significantly less likely than those with a negative or no test result to receive antibiotics (32.6% vs. 64.8% and 61.8%; |
| Iyer et al., 2006 [ | Prospective, quasi-RCT; febrile children at risk for serious bacterial illness (SBI) based on age and temperature and who presented to a paediatric ED during an influenza outbreak, n = 700 | To determine the effect of point-of-care testing (POCT) for influenza on the physician management of febrile children | Quickvue Influenza Test | No significant differences were demonstrated between the POCT and ST groups with respect to laboratory tests ordered, chest radiographs obtained, antibiotic administration, inpatient admission, return visits to the pediatric ED, lengths of stay, or visit-associated costs. |
| Jacob et al., 2021 [ | Retrospective, observational study; patients included were aged < 16 years who had Influenza-like illness, n = 1451 | Assess whether location of rapid influenza diagnostic testing (RIDT) for patients with influenza-like illness has an impact on ED treatment time or ancillary testing | BD Veritor digital immunoassay (bedside) or Quidel Sophia fluorescence immunoassay (laboratory) | Location of RIDT may not have a significant impact on treatment time, ancillary testing and treatment with antibiotics. When RIDT was not performed, patients had the shortest treatment time. |
| May et al., 2019 [ | Prospective, patient-oriented, pilot RCT; patients ≥ 12 months old, had symptoms of upper respiratory infection or influenza- like illness, and were not on antibiotics, n = 191 | Evaluate whether having a RDT result available during the ED visit would have a significant impact on management and outcomes in patients with clinical signs and symptoms of acute respiratory tract infection | BioFire FilmArray Respiratory Panel 2 | Twenty (22%) RDT patients and 33 (34%) usual care patients received antibiotics during the ED visit (–12%; 95% confidence interval, –25% to 0.4%; |
| Ozkaya et al., 2009 [ | RCT; Patients aged 3 to 14° years presenting to ED with fever and cough, coryza, myalgias and/or malaise, n = 97 | Determine the influence of rapid diagnosis of influenza on antibiotic prescribing to children presenting with influenza-like illness in the ED | Influenza A/B Rapid Test | Patients in RDT group were less likely to be prescribed antibiotics when compared to those in usual care (32% vs. 100%, respectively, |
| Poehling et al., 2006 [ | RCT; patients < 5 years of age presenting with any of the following symptoms: cough, rhinorrhoea, wheezing, difficulty breathing, fever, sore throat, apnoea, or ear pain, n = 468 | Determine whether a point-of-care rapid influenza test impacts the diagnostic evaluation and treatment of children with acute respiratory illnesses | PCR + RDT (QuickVue Influenza Test) | In the ED, fewer children in the rapid test group had diagnostic tests ordered than in the no rapid test group (39% vs. 51%, |
| Rao et al., 2021 [ | RCT; children aged 1 month to 18 years presenting to an ED with ILI, n = 931 | Determine whether RDT testing leads to decreased antibiotic use and healthcare use among children with influenza-like illness in an ED | BioFire FilmArray RP2 Panel | The use of RDT testing in the ED for ILI did not decrease antibiotic prescribing in this randomized clinical trial (RR, 1.1; 95% CI, 0.9–1.4). There is a limited role for RRP pathogen testing in children in this setting. |
| Rogan et al., 2017 [ | NCBA; consecutive paediatric patients <18 years of age who had a respiratory virus PCR panel by nasopharyngeal swab, n = 28 | Determine the impact of bedside PCR on paediatric acute respiratory infection management | PCR test for respiratory viruses | Physicians would have decreased ED LOS by 33 min, ordered fewer tests (18%; |
| Rogers et al., 2015 [ | NCBA; patients who aged 3 months to 21 years who had respiratory panel test, n = 771 | Determine if implementation of the RDT led to a shorter time to the test result and expanded panel, results in different outcomes for children admitted to the hospital with an acute respiratory tract illness | BioFire FilmArray RP2 Panel | The RRP decreases the duration of antibiotic use ( |
| Sharma et al., 2002 [ | Retrospective cohort: all children 2 to 24 months of age, with a temperature higher than 39 °C who had a positive influenza virus type A test result using an enzyme-linked immunosorbent assay, n = 72 | Determine the effect of rapid diagnosis of influenza virus type A on the clinical management of febrile infants and toddlers in a paediatric ED | Rapid detection of influenza virus type A infection by enzyme-linked immunosorbent assay (ELISA) | Fewer patients in the early diagnosis group received ceftriaxone sodium compared with those in the late diagnosis group (2% vs. 24%, |
| Zhu et al., 2019 [ | Retrospective cohort: children 1 month to 18 years of age with uncomplicated acute respiratory tract infections admitted into the hospital or seen in the ED, n = 939 | Assess whether RPP decreases antibiotic days of therapy and length of hospital stay for paediatric patients with acute respiratory infections | BioFire FilmArray RP2 Panel | Fewer RPP-positive patients were prescribed antibiotics on discharge when compared with RPP-negative patients (8.8% vs. 41.1%; χ2 = 13.57; |
ICROMS Quality Criteria for Application per Study Design.
| Quality Criteria | Study Design ** | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dimension | Specific Criteria * | RCT | CBA | CITS | NCITS | NCBA | CS | QUAL | |
| 1 | Clear aims and justification | a. Clear statement of the aims of the research? | YY | YY | YY | YY | YY | YY | YY |
| b. Rationale for number of pre- and postintervention points or adequate baseline measurement | N | N | Y | YY | YY | N | N | ||
| c. Explanation for lack of control group | N | N | N | Y | Y | N | N | ||
| d. Appropriateness of qualitative methodology | N | N | N | N | N | N | Y | ||
| e. Appropriate study design | N | N | N | N | N | N | YY | ||
| 2 | Managing bias in sampling or between groups | a. Sequence generation | YY | N | N | N | N | N | N |
| b. Allocation concealment | YY | N | N | N | N | N | N | ||
| c. Justification for sample choice | N | N | N | YY | YY | N | N | ||
| d. Intervention and control group selection designed to protect against systematic difference/selection bias | N | YY | N | N | N | N | N | ||
| e. Comparability of groups | N | N | N | N | N | YY | N | ||
| f. Sampling and recruitment | N | N | N | N | N | N | YY | ||
| 3 | Managing bias in outcome measurements and blinding | a. Blinding | YY | N | N | N | N | N | N |
| b. Baseline measurement and protection against selection bias | N | YY | N | N | N | N | N | ||
| c. Protection against contamination | N | YY | N | N | N | N | N | ||
| d. Protection against secular changes | N | N | YY | N | N | N | N | ||
| e. Protection against detection bias: Blinded assessment of primary outcome measures | Y | Y | Y | Y | Y | Y | N | ||
| f. Reliable primary outcome measures | Y | Y | Y | Y | Y | Y | Y | ||
| g. Comparability of outcomes | N | N | N | N | N | YY | N | ||
| 4 | Managing bias in follow-up | a. Follow-up of subjects (protection against exclusion bias) | Y | N | N | N | N | N | N |
| b. Follow-up of patients or episodes of care | Y | N | N | N | N | N | N | ||
| c. Incomplete outcome data addressed | Y | Y | Y | Y | Y | YY | Y | ||
| 5 | Managing bias in other study aspects | a. Protection against detection bias: Intervention unlikely to affect data collection | Y | Y | Y | Y | Y | N | N |
| b. Protection against information bias | N | N | N | N | N | Y | N | ||
| c. Data collection appropriate to address research aims | N | N | N | N | N | N | Y | ||
| d. Attempts to mitigate effects of no control | N | N | N | YY | YY | N | N | ||
| 6 | Analytical rigour | a. Sufficient data points to enable reliable statistical inference | N | N | YY | N | N | N | N |
| b. Shaping of intervention effect specified | N | N | Y | N | N | N | N | ||
| c. Analysis sufficiently rigorous/free from bias | Y | Y | Y | Y | Y | Y | Y | ||
| 7 | Managing bias in reporting/ethical considerations | a. Free of selective outcome reporting | Y | Y | Y | Y | Y | Y | Y |
| b. Limitations addressed | Y | Y | Y | Y | Y | Y | Y | ||
| c. Conclusions clear and justified | Y | Y | Y | Y | Y | Y | Y | ||
| d. Free of other bias | Y | Y | Y | Y | Y | Y | Y | ||
| e. Ethics issues addressed | Y | Y | Y | Y | Y | Y | Y | ||
* Quality criteria applicability to study designs: Y = criteria to be included in quality assessment for study design; YY = mandatory criteria to be met for quality assessment; N = criteria not to be applied in quality assessment for study design. ** Study designs: RCT = randomised controlled trial; CBA = controlled before-after; CITS = controlled interrupted time series; CS = cohort study; NCITS = noncontrolled interrupted time series; NCBA = noncontrolled before-after; QUAL = qualitative.
ICROMS Decision Matrix—Mandatory Criteria and Minimum Score of Study Type for Inclusion in Review.
| Study Design * | Mandatory Criteria | Minimum Score ** |
|---|---|---|
| RCT, cRCT | 1a, 2a, 2b, 3a | 22 |
| CBA | 1a, 2d, 3b, 3c | 18 |
| CITS | 1a, 3d, 6a | 18 |
| NCITS | 1a, 1b, 2c, 5d | 22 |
| NCBA | 1a, 1b, 2c, 5d | 22 |
| Cohort | 1a, 2e, 3g, 4c | 18 |
| Qualitative | 1a, 1e, 2f | 16 |
Studies must meet mandatory criteria and a minimum score to be included in review. * Study Designs: RCT = randomised controlled trial; CBA = controlled before-after; CITS = controlled interrupted time series; cRCT = cluster-randomized controlled trial; NCITS = noncontrolled interrupted time series; NCBA = noncontrolled before-after. ** Scores applicable to each criteria: Yes (criterion met) = 2 points; Unclear (unclear whether or not the criterion is met) = 1 point; No (criterion not met) = 0 points.
Score Attributed to Included Articles. Diagnostic Stewardship–The Impact of Rapid Diagnostic Testing for Paediatric Respiratory Presentations in the Emer-gency Setting: A Systematic Review.
| Study | Study Design | Minimum Score Required | Study Score |
|---|---|---|---|
| Ayanruoh et al. | Cohort | 18 | 26 |
| Bird et al. | NCBA | 22 | 30 |
| Busson et al. | Cohort | 18 | 28 |
| Cardoso et al. | Cohort | 18 | 28 |
| Crook et al. | CBA | 18 | 27 |
| Doan et al. | RCT | 22 | 31 |
| Echavarria et al. | RCT | 22 | 28 |
| Esposito et al. | RCT | 22 | 28 |
| Iyer et al. | RCT | 22 | 28 |
| Jacob et al. | Cohort | 18 | 27 |
| May et al. | RCT | 22 | 32 |
| Ozkaya et al. | RCT | 22 | 28 |
| Poehling et al. | RCT | 22 | 30 |
| Rao et al. | RCT | 22 | 32 |
| Rogan et al. | NCBA | 22 | 28 |
| Rogers et al. | NCBA | 22 | 32 |
| Sharma et al. | Cohort | 18 | 27 |
| Zhu et al. | Cohort | 18 | 28 |